- Previous Close
0.9250 - Open
0.9316 - Bid --
- Ask --
- Day's Range
0.9250 - 0.9676 - 52 Week Range
0.8010 - 2.1200 - Volume
160,152 - Avg. Volume
288,186 - Market Cap (intraday)
70.527M - Beta (5Y Monthly) 2.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date Mar 10, 2025 - Mar 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
clearsidebio.com30
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: CLSD
View More
Performance Overview: CLSD
Trailing total returns as of 2025-01-17, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLSD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLSD
View MoreValuation Measures
Market Cap
70.53M
Enterprise Value
47.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.50
Price/Book (mrq)
--
Enterprise Value/Revenue
6.20
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.05%
Return on Equity (ttm)
--
Revenue (ttm)
7.52M
Net Income Avi to Common (ttm)
-33.46M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
29.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-17.5M
Research Analysis: CLSD
View MoreCompany Insights: CLSD
CLSD does not have Company Insights
Research Reports: CLSD
View MoreDaily – Vickers Top Buyers & Sellers for 04/22/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/12/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/08/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.